Navigation Links
Leg Ulcers-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leg Ulcers-Pipeline Insights, 2014

http://www.reportlinker.com/p02278621/-Leg-Ulcers-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Leg Ulcers-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Leg Ulcers. This report provides information on the therapeutic development based on the Leg Ulcers dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Leg Ulcers
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Leg Ulcers pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Leg Ulcers and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Leg Ulcers
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Leg Ulcers pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Leg Ulcers Overview
- Leg Ulcers Pipeline Therapeutics
- Leg Ulcers Therapeutics under Development by Companies
- Leg Ulcers Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Leg Ulcers Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Leg Ulcers Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Leg Ulcers Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Leg Ulcers – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leg Ulcers – Discontinued Products
- Leg Ulcers – Dormant Products
- Companies Involved in Therapeutics Development for Leg Ulcers
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Leg Ulcers, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Leg Ulcers Assessment by Monotherapy Products
- Leg Ulcers Assessment by Combination Products
- Leg Ulcers Assessment by Route of Administration
- Leg Ulcers Assessment by Stage and Route of Administration
- Leg Ulcers Assessment by Molecule Type
- Leg Ulcers Assessment by Stage and Molecule Type
- Leg Ulcers Therapeutics – Discontinued Products
- Leg Ulcers Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Leg Ulcers, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Leg Ulcers Assessment by Monotherapy Products
- Leg Ulcers Assessment by Combination Products
- Leg Ulcers Assessment by Route of Administration
- Leg Ulcers Assessment by Stage and Route of Administration
- Leg Ulcers Assessment by Molecule Type
- Leg Ulcers Assessment by Stage and Molecule Type

To order this report: Leg Ulcers-Pipeline Insights, 2014
http://www.reportlinker.com/p02278621/-Leg-Ulcers-Pipeline-Insights-2014.html
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Adenocarcinoma-Pipeline Insights, 2014
2. Lung Disease-Pipeline Insights, 2014
3. Liver Transplantation-Pipeline Insights, 2014
4. Liver Fibrosis-Pipeline Insights, 2014
5. Liver Diseases-Pipeline Insights, 2014
6. Liver Cirrhosis-Pipeline Insights, 2014
7. Liposarcoma -Pipeline Insights, 2014
8. Lipodystrophy-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):